This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Treatment of enterohaemorrhagic E.coli

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Seek expert advice.

If a child is suspected of having an E. coli 0157 infection then urgent assessment by a paediatrician is indicated - hospital admission should be considered if features suggestive of E. coli O157 (eg, acute bloody diarrhoea and severe abdominal pain; children aged less than 5 years are at greatest risk of developing HUS, usually 1 week after onset of bloody diarrhoea).

Treatment is supportive.

Non-specific supportive therapy, including hydration, is important.

Antimotility drugs are contraindicated because of the increased risk of development of haemolytic uraemic syndrome (HUS)

  • avoid antidiarrhoeal drugs and opioid analgesics
    • there is an increased risk of developing HUS or other complications of E.coli infection associated with use of antimotility agents and opioid analgesics

During the week after the onset of the diarrhoea, the patient should be monitored for features of HUS (oliguria, oedema and weight gain, pallor; monitor blood count, platelets, renal function and electrolytes).

Antibiotics should not be used to treat this infection.

Reference:

  • 1) CMO's Update 27 (August 2000), 6.
  • 2) Pennington, T. H. (2014). E. coli O157 outbreaks in the United Kingdom: past, present, and future. Infection and Drug Resistance, 7, 21-222.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.